The ethics and economics of health care

Journal of Medicine and Philosophy

Volumn 30, Issue 6, 2005, Pages 571-578

  Capaldi, Nicholas ^a  

^a UNIVERSITY OF NEW ORLEANS   (United States)

Author keywords

Free market; Medical innovation

Indexed keywords

CONSUMER; ECONOMIC ASPECT; ECONOMICS; GOVERNMENT REGULATION; HEALTH CARE; HEALTH CARE PLANNING; MARKETING; MEDICAL ETHICS; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; PROFIT; QUALITY OF LIFE; REVIEW;

ANALYTICAL APPROACH; BIOMEDICAL AND BEHAVIORAL RESEARCH; HEALTH CARE AND PUBLIC HEALTH;

BIOMEDICAL RESEARCH; COMMERCE; DELIVERY OF HEALTH CARE; ECONOMICS; HUMANS; TECHNOLOGY, MEDICAL;

EID: 30544454897     PISSN: 03605310     EISSN: None     Source Type: Journal    
DOI: 10.1080/03605310500421371     Document Type: Review

References (15)

1. Aoki, N. (2001, January 17). Brainstorm center to encourage innovation, Pfizer puts its corporate muscle behind an entrepreneurial unit in Cambridge biotechnology: Curagen, Bayer AG Ink drug pact worth up to $1.34B. The Boston Globe, D1.
2. Capaldi, N. (2004). Ethical foundations of free market societies. The Journal of Private Enterprise, 20, 30-54.
3. Danzon, P.M. (1997). Pharmaceutical price regulation: National policies versus global interests. Washington, DC: AEI Press.
4. Descartes, R. (1637). Discourse on method.
5. European Convention. (2003). Article III-129. [On-line]. Available http://european-convention.eu.int.
6. The Economist. (2002, December 14). Innovation's golden goose. [On-line]. Available http://www.economist.com/science/tq/displayStory.cfm?Story_id= 1476653.
7. Lichtenberg, F.R. (1996). The effect of pharmaceutical utilization and innovation on hospitalization and mortality. In NBER Working Paper 5418. Cambridge: National Bureau of Economic Research.
8. Locke, J. (1980). Second treatise on government. Indianapolis: Hackett Press.
9. Masters, B. (2004, October 1). Wall Street batters Merck: Stock price falls 27% after drug firm withdraws Vioxx. The Washington Post, E01.
10. Matthews, Jr., M. (2003). Prescription drug prices and profits. IPI Center for Technology and Freedom, 15.
11. Petroni, A. (2006). Perspectives for freedom of choice in bioethics and health care in Europe. In H.T. Engelhardt, Jr. (ed.), A global bioethics: Why there is none. Salem, MA: M&M Scrivener Press.
12. Smith, A. (1776). The wealth of nations. [On-line]. Available http://socserv2.soc-sci.mcmaster.ca/[*x0223C]econ/ugcm/3113/smith/wealth.
13. Treaty of Amsterdam. (1999). Article 152. [On-line]. Available www.europa.eu.int/ abc/obj/amst/en.
14. Trevino, R., & Higgs, R. (1992). Profits of U.S. defense contractors. [On-line], Available http://www.independent.org/publications/article.asp?id= 129.
15. Verespej, M.A. (1999, June 7). By the numbers. Industry Week.